REVIVA PHARMACEUTICALS
Recommended Videos
Upside for Reviva Assuming $8 Billion Buyout, video 3 of 4 – Dec 23 2023
SaveChangeWorld (SCW) Videos & Reports
*Includes Dynasty Wealth Content
| SCW Produced* | Date | View Link | Duration |
|---|---|---|---|
| Reviva Pharma, not a tax loss sales buying opportunity | Dec 28 2024 | https://share.vidyard.com/watch/9BaDZEn16i77reTSaC73zh | 2:07 |
| Year End Trading Strategy: INVU, AXIL, RVPH, NTRB, HSDT, GRST & AKEMF | Dec 14 2024 | https://share.vidyard.com/watch/pBiQKx3q5PhMDRipHXz56m | 8:12 |
| Reviva Pharma (RVPH) Update | July 27 2024 | https://share.vidyard.com/watch/1tbJb73tLD4Px9pXHvVhWt? | 0:57 |
| Reviva Shares Hitting Resistance | May 25 2024 | https://share.vidyard.com/watch/k3Hd1SbXbtqeCod7EpjP5U | 1:34 |
| Reviva shares, Great Buy | Apr 27 2024 | https://share.vidyard.com/watch/JjyzzJRQVtVKiV1wi5Kaia | 5:42 |
| Reviva Pharma (RVPH) Update | Jan 20 2024 | https://share.vidyard.com/watch/CErDVe2vBPHwHWNt8yn4iw | 3:24 |
| Why Reviva could soon be Swallowed by Big Pharma, video 2 of 4 | Dec 23 2023 | https://share.vidyard.com/watch/aXbpfWAjo6FCCX6uJMuUUm | 21:32 |
| Upside for Reviva Assuming $8 Billion Buyout, video 3 of 4 | Dec 23 2023 | https://share.vidyard.com/watch/FFkUvvowAh9Y3czbWpGuBA | 5:39 |
| Reviva Pharma (RVPH) Update | Dec 2 2023 | https://share.vidyard.com/watch/WwzFUtxJsfKAouFYhGbhFh | 3:04 |
| Reviva (RVPH) Update | Oct 21 2023 | https://share.vidyard.com/watch/ffaYpGoawfp7CaZkaXnQeM | 5:54 |
| *Includes Dynasty Wealth Content |
Reviva Pharma & SaveChangeWorld.com (SCW) Videos & Reports, etc.
*Includes Dynasty Wealth Content
Reviva Pharma, not a tax loss sales buying opportunity – Dec 28 2024 – 2:07
https://share.vidyard.com/watch/9BaDZEn16i77reTSaC73zh
Year End Trading Strategy: INVU, AXIL, RVPH, NTRB, HSDT, GRST & AKEMF – Dec 14 2024 – 8:12
https://share.vidyard.com/watch/pBiQKx3q5PhMDRipHXz56m
Reviva Pharma (RVPH) Update – July 27 2024 – 0:57
https://share.vidyard.com/watch/1tbJb73tLD4Px9pXHvVhWt
Reviva Shares Hitting Resistance – May 25 2024 – 1:34
https://share.vidyard.com/watch/k3Hd1SbXbtqeCod7EpjP5U
Reviva shares, Great Buy – Apr 27 2024 – 5:42
https://share.vidyard.com/watch/JjyzzJRQVtVKiV1wi5Kaia
Reviva Pharma (RVPH) Update – Jan 20 2024 – 3:24
https://share.vidyard.com/watch/CErDVe2vBPHwHWNt8yn4iw
Why Reviva could soon be Swallowed by Big Pharma, video 2 of 4 – Dec 23 2023 – 21:32
https://share.vidyard.com/watch/aXbpfWAjo6FCCX6uJMuUUm
Upside for Reviva Assuming $8 Billion Buyout, video 3 of 4 – Dec 23 2023 – 5:39
https://share.vidyard.com/watch/FFkUvvowAh9Y3czbWpGuBA
Reviva Pharma (RVPH) Update – Dec 2 2023 – 3:04
https://share.vidyard.com/watch/WwzFUtxJsfKAouFYhGbhFh
Reviva (RVPH) Update – Oct 21 2023 – 5:54
https://share.vidyard.com/watch/ffaYpGoawfp7CaZkaXnQeM
GENERAL INFORMATION
Addressing Significant Unmet Medical Needs
Developing next-generation therapeutics for diseases representing significant unmet medical needs and a burden to society, patients and their families.
Discovering and Developing New Therapies
Reviva Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing novel therapies for central nervous system, respiratory, and metabolic diseases of huge unmet need. They are committed to developing better, safer, and more effective treatments that can have a real impact on the lives of our patients.
Better Patient Outcomes, Better Safety Profiles
Using chemical genomics driven technology, Reviva is leveraging scientific innovations to discover and develop new medicines with better therapeutic options for patients in need.
Delivering Safe and Efficacious Treatment Options
Reviva’s lead drug candidate, brilaroxazine (RP5063), is in clinical development for multiple unmet neuropsychiatric indications including schizophrenia, bipolar disorder, major depressive disorder, behavioral and psychotic symptoms in Alzheimer’s disease, Parkinson’s disease psychosis, and attention deficit hyperactivity disorder (ADHD).
Corporate Presentation
